NOVAREMED-AG
5.3.2019 18:00:09 CET | Business Wire | Press release
The Board of Directors of Novaremed AG, a Swiss clinical-stage biopharmaceutical company, is pleased to announce the appointment of Nicholas Draeger as the new CEO. Nicholas will assume the role effective immediately. Former CEO and Founder, Eli Kaplan, will take a new role in the company to support the company’s further development of its lead asset and expansion of its drug pipeline.
“We are delighted to welcome Nicholas as the new CEO of Novaremed AG. His extensive experience in building and leading teams will be key to successful further development of Novaremed’s lead asset and the company itself. On behalf of the Board, I like to thank Eli for successfully building Novaremed through the past years and for leading the company through a period of significant change. His extensive knowledge of the lead asset will be an invaluable resource and support for the further development of the company.”, said Harry Welten, Chairman of the Board of Novaremed AG.
Nicholas Draeger, 53, has over 25 years of experience spanning the pharmaceutical, equity brokerage, investment management and processed food industries. He started his pharmaceutical career with research and global business development roles at Roche and Recordati. Following which, he joined Credit Agricole Indosuez Cheuvreux, a leading pan-European broker as Head of Biotechnology research. His healthcare portfolio management roles followed thereafter, first as a Portfolio Manager at BB Biotech and then as a Partner at Adamant BioMedical Investments, two of the leading European healthcare institutional investors. He has been leading as CEO, Nurevas International, a processed food company in Ghana, which he co-founded in 2011. Nicholas holds a BSc in Chemical Engineering from the University of Natal, South Africa, a PhD in BioChemical Engineering from the University of Cambridge, UK and an MBA from Warwick Business School, UK.
“I am delighted to have joined the Novaremed team. I look forward to working with the management team and board to continue to build on the excellent foundations that have been created to date. I would like to thank Eli for having founded Novaremed and helped guide this excellent company to this point.”, said Nicholas Draeger.
Eli Kaplan, Former CEO and Founder of Novaremed AG, commented: “I congratulate Nicholas for his new role and wish him the very best for leading Novaremed forward in successfully achieving its near- and long-term goals.”
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed is developing NRD.E1, an orally-active small molecule with a differentiated mechanism of action for the treatment of Diabetic Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DPN, expected to start in Q4 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005776/en/
Contact:
Subhasis Roy, Chief Operating Officer Tel: +41 79 2075715 Email: subhasis.roy@novaremed.com Web: www.novaremed.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
Wasabi and Liverpool FC Renew Multi-year Partnership to Scale Global Fan Growth27.5.2026 15:00:00 CEST | Press release
Wasabi remains official cloud storage partner of Liverpool FC during its worldwide expansion, helping fuel the Club’s global digital content strategy Wasabi Technologies, the hot cloud storage company, today announced a multi-year extension of its partnership with Liverpool Football Club (LFC), deepening its role as the club’s Official Cloud Storage Partner. The renewed deal will see Wasabi help power the next phase of LFC’s global content strategy through Wasabi AiR, the intelligent media storage service, enabling the club to move faster, scale smarter, and deliver more personalised fan experiences that bring supporters across the world closer to the club. Together, the partnership empowers LFC to create, store, find, and publish content faster, helping to deliver rapid match and social output and serve its global fanbase with richer, more dynamic storytelling. Meanwhile, LFC serves as a strategic partner in Wasabi’s worldwide expansion, with brand visibility that grows Wasabi’s partn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom